Why Is Kodiak Sciences (KOD) Stock Up +125.44% Today?
Key Takeaways
- KOD shares surged roughly 125%, trading near $72.93 in morning action versus a prior close of $32.35.
- The primary catalyst was positive topline data from the Phase 3 DAYBREAK study in wet age-related macular degeneration (AMD).
- Both investigational therapies, Zenkuda and KSI-501, met their primary endpoints for non-inferiority in visual acuity versus aflibercept (Eylea).
- The move came on a company-specific catalyst, with major U.S. indexes trading lower on the day.
- Investors are now watching Kodiak's planned regulatory submission, expected in the fourth quarter of 2026.
Opening Summary
Kodiak Sciences Inc. (KOD), a clinical-stage biopharmaceutical company focused on novel therapies for retinal vascular diseases, delivered one of its most dramatic trading sessions on record Monday after reporting successful late-stage trial results. Shares of the Palo Alto, California-based company were trading around $72.93 in morning action, up from a prior-session close of $32.35 — a gain of roughly 125%. The surge followed topline results from the Phase 3 DAYBREAK study, in which two of the company's investigational eye-disease candidates both hit their primary endpoints in patients with wet age-related macular degeneration.
Catalyst Breakdown: Positive DAYBREAK Phase 3 Data
The sharp rally was driven by company-specific news. Kodiak reported that its pivotal DAYBREAK study, which evaluated two parallel investigational arms against the active comparator aflibercept (the molecule behind Regeneron Pharmaceuticals' (REGN) blockbuster Eylea), achieved its goals. Zenkuda (tarcocimab tedromer), the company's lead anti-VEGF antibody biopolymer conjugate, met its primary endpoint of non-inferiority in visual acuity gains with a highly statistically significant p-value, and showed durability with a meaningful proportion of patients maintained on six-month dosing intervals. Separately, KSI-501 (tabirafusp alfa tedromer), an anti-IL-6/VEGF bispecific therapy, also met its vision primary endpoint as well as an anatomical key secondary endpoint.
Because DAYBREAK simultaneously evaluated two molecularly distinct candidates in a single registrational trial, one readout effectively de-risked two separate market opportunities. Zenkuda had already generated positive Phase 3 results across diabetic retinopathy and retinal vein occlusion, so a successful wet AMD readout completes the picture for what the company has described as a BLA-ready, multi-indication profile.
Regulatory Path and Commercial Potential
The market reaction reflects a significant reduction in the binary risk that has weighed on the stock. Kodiak said it plans to submit a multi-indication biologics license application (BLA) for Zenkuda in the fourth quarter of 2026, encompassing five positive Phase 3 studies across wet AMD, diabetic retinopathy and retinal vein occlusion. If approved, Zenkuda would enter a retinal vascular disease market the company estimates at roughly $15 billion, competing against established anti-VEGF therapies where durability and reduced treatment burden remain key differentiators. A positive safety profile — including a low rate of intraocular inflammation — further supported the bullish narrative.
Market Context and Trading Activity
The move stood out because it ran counter to the broader tape. While KOD shares were soaring, major U.S. equity indexes were trading lower, underscoring that the rally was entirely idiosyncratic rather than a function of risk-on sentiment. Trading volume was exceptionally heavy as investors repriced the stock following the binary clinical readout, with shares gapping dramatically above their prior 52-week range. The stock, which had traded as low as $10.94 over the past year, blew through its previous 52-week high of $47.84 and reached levels not seen in roughly four years. The move was characteristic of a clinical-stage biotech re-rating, where a single positive data point can rapidly compress a valuation discount that had built up ahead of the readout.
What Comes Next for KOD
Attention now shifts from the clinical data to execution. Near-term milestones include the planned BLA submission for Zenkuda in the fourth quarter of 2026, along with additional pipeline catalysts — most notably Phase 3 results from the first KSI-101 study in macular edema secondary to inflammation, expected in December 2026, and the ongoing ALTO pivotal program for KSI-501 in diabetic macular edema. Investors will also monitor regulatory feedback, manufacturing readiness, and the company's capital position as it transitions toward potential commercialization. As a pre-revenue biotech, Kodiak still faces financing and execution risk, and the durability of the share-price gains will depend on a clean regulatory review and successful launch strategy.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. The bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving investors a way to explore algorithmic approaches to the market. Visit the Trending AI Robots page to see which strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
KOD in upward trend: 10-day moving average broke above 50-day moving average on September 29, 2026
The 10-day moving average for KOD crossed bullishly above the 50-day moving average on September 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 28, 2026. You may want to consider a long position or call options on KOD as a result. In 55 of 67 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for KOD just turned positive on September 24, 2026. Looking at past instances where KOD's MACD turned positive, the stock continued to rise in 34 of 39 cases over the following month. The odds of a continued upward trend are 87%.
KOD moved above its 50-day moving average on September 28, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +8.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where KOD advanced for three days, in 235 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KOD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
KOD broke above its upper Bollinger Band on September 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KOD entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. KOD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (92.593) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KOD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel therapies for the treatment of retinal disease
Industry Biotechnology
Advertisement